Read there filings:
I can lead a horse to water but I can't make it drink. Read the last sentence of this PR
The Company expects that its Topical Cream will be Market-Ready in Q2 2017
PETACH TIKVA, Israel, March _____, 2017 /PRNewswire /OWC Pharmaceutical Research Corp. (OTCQB: OWCP), ("OWC" or the "Company"), an Israeli-based developer of cannabinoid-based therapies targeting a variety of medical conditions and disorders, today announced the highly promising results of its topical cream efficacy tests following months of study and scientific analysis.
In October 2016, OWC announced that it was in the final phase of pre-clinical efficacy testing for its topical psoriasis cream and also announced a parallel test to assess the efficacy of the formulation in treating psoriasis in human skin tissue. The recent results are highly promising, showing significant reduction of several inflammation markers specific to psoriasis.
As a result of the promising results of our psoriasis tests, our Chairman and CEO, Mr. Mordechai Bignitz, has directed OWC's scientific team to submit an operating plan within 60 to 90 days to conduct double-blind efficacy tests of our cannabinoid-based topical cream on other skin disorders and conditions
Dr. Yehuda Baruch, the Company's Chief Science Officer and Director of Research and Regulatory Affairs, commented "As a practicing physician and a scientist who has been treating patients with cannabis for medical purposes for more than two decades, I am truly excited by our success to date and, more importantly, I am thrilled to be part of a professional scientific study on humans that should actually validate what I have believed and experienced for years - Cannabis helps treat a multitude of health conditions."
Dr. Sharon Rozenblat, PhD in Biochemistry, a member of OWC Scientific Advisory Board added, "After many years of being actively involved in research and development of innovative dermatological treatments and being exposed to the many scientific articles and peer reviewed works and publications regarding skin conditions and diseases, I would like to emphasize my personal belief that OWC's psoriasis results have been indeed unique in the most positive sense." Dr. Rozenblat continued by stating "while there is still scientific work to be done, as a scientist I am extremely excited to be part of OWC's study that appears to be a highly possible breakthrough that can improve the life of psoriasis patients and, possibly, patients with other skin conditions".
AI
